Published April 2017. This article covers full-year 2016 results for GSK Biologicals, Sanofi Pasteur, Merck & Co and Pfizer Vaccines - the four major commercial vaccine manufacturers. Currency fluctuations affect year-on-year comparisons as GSK and Sanofi report in GBP and EUR respectively.
The Industry's Revenue Plateau
According to VacZine Analytics' analysis, the top four vaccine manufacturers (excluding SPMSD) sold around $23bn of vaccines for the full year 2016 - a figure barely changed from FY2015. In fact, the industry has operated in the $20-23bn per year revenue range since 2010. Historically, big gains occurred with the launch of Gardasil in the US (2006), the H1N1 pandemic (2009/10), and PCV-13 life-cycle management (2014/15) - but many of these gains were not sustained.
Combined revenues of GSK Biologicals, Sanofi Pasteur, Merck & Co and Pfizer Vaccines in full-year 2016. The industry has operated in the $20-23bn range since 2010, with growth driven by episodic LCM rather than structural expansion.
GSK: Bexsero Breaks Out
GSK Biologicals reported $6,245m revenues in FY2016 (£4,592m), with sales growing 14% on a reported basis. The serogroup B meningococcal vaccine, Bexsero, stood out with strong yearly sales of $530m - estimated at more than 10 million doses globally in two years. The vaccine sold $175m in FY2015. Strong growth of private channel sales in the EU and Latin America supplemented the public UK infant programme. In the US, the ACIP permissive recommendation for MenB in adolescents drove ~30% of global Bexsero sales ($166m). Real-world effectiveness data showing 83% case reduction in the first year of the UK infant programme bolstered the product's profile significantly.
GSK also filed its new shingles vaccine, Shingrix, in the US, Europe, and Canada in November 2016, stating it expected the product to drive approximately one-third of their growth to 2020.
Sanofi: Dengvaxia's Difficult First Year
Sanofi Pasteur reported €4,577m of vaccine sales in FY2016, up 3.7%. For influenza, the franchise delivered a record year with €1,521m sales and 70 million doses shipped in the US. However, Sanofi's 'first in class' dengue vaccine, Dengvaxia, sold only €55m - disappointing despite approval in 14 countries. Only two regional vaccination programmes had been initiated (Paraná, Brazil and Regions III, IVA and NCR, Philippines), with the WHO SAGE's restrictive recommendation for those aged nine and over in high-seroprevalence settings causing hesitancy among national policymakers.
Merck & Co and Pfizer
VacZine Analytics calculates that Merck & Co sold $6.2bn worth of vaccines in FY2016, an increase of 10% over 2015, driven by Pneumovax-23 ($641m) and Gardasil-9 ($2,173m). Pfizer Vaccines reported $6,071m revenues, a decline on the $6,454m the year prior, attributable largely to the Prevnar/Prevenar-13 franchise in the US reaching the end of the exploitable adult 'catch-up' opportunity. The company noted that ~50% of the eligible patient pool had already been vaccinated.
"Bexsero is only part of one major funded national immunisation programme and must be attracting private customers - this sounds rather like the early days of Dengvaxia."
Outlook
Bexsero, approved in 2012 in the EU, has taken time to scale but can no longer be considered a minor product (>$500m per year). It demonstrates that genuine vaccine innovation - backed by compelling real-world effectiveness data - can achieve significant commercial scale even without universal public programme adoption. The question for Dengvaxia is whether equivalent 'real use' data from Brazil and the Philippines will lift the product to a similar trajectory. There will always be a future for true vaccine innovation.
This article is available in VacZine Analytics' Expert News archive as published in April 2017. All revenue figures derived from corporate press releases.